[Closure of secundum XXXX by the Amplatzer occluder device].

@entity1 @entity997 @entity2224 @entity1001 @entity118 @entity943 @entity715 @entity1002
OBJECTIVES: Percutaneous closure of secundum @entity118 ( @entity118 ) has become an important alternative treatment to surgery. We evaluated our clinical experience with, and short-term results of transcatheter closure of ASDs with the Amplatzer septal occluder in adult @entity1 . STUDY DESIGN: The study included 52 @entity1 (36 @entity1 , 16 @entity1 ; mean age 33  14 years; range 14 to 69 years) who underwent transcatheter @entity118 closure with the Amplatzer occluder device. The mean @entity118 diameter measured by transesophageal echocardiography was 19.5  5.7 mm and the mean device diameter was 24.5  5.7 mm. All the @entity1 were assessed clinically and echocardiographically one month after the procedure. RESULTS: Transcatheter @entity118 closure was successfully performed in 48 @entity1 (92.3%) and failed in four @entity1 (7.7%). Echocardiographic controls showed significant decreases in @entity997 , @entity1001 , and pulmonary artery pressure (p=0.003, p=0.026, and p=0.0001, respectively). Functional capacity of the @entity1 also showed significant improvements (p=0.0001). After implantation, residual shunts were detected in four @entity1 , all of which disappeared one month after the procedure. Major complications were seen in two @entity1 . One @entity1 developed @entity2224 immediately after the procedure due to device embolization. One @entity1 with @entity1002 developed device @entity715 due to cessation of dual antiplatelet therapy, which was successfully treated by anticoagulation therapy. @entity943 was not observed in any @entity1 . CONCLUSION: Percutaneous closure of secundum ASDs with the Amplatzer occluder device is a safe and effective procedure with a high success rate.
